Drugs / PRO-203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07641634 | Oct 2025 → Jan 2027 expected | systemic sclerosis | Prolium Bioscience, Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRO-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07641634 ↗ |
| Route | Subcutaneous | “PRO-203 administered subcutaneously” NCT07641634 ↗ |